Read PLR Content Marketing Ireland: September 2016

Friday, September 30, 2016

Atenolol-CT

Atenolol-CT may be available in the countries listed below.

Ingredient matches for Atenolol-CT

Atenolol

Atenolol is reported as an ingredient of Atenolol-CT in the following countries:

Germany

Luxembourg

International Drug Name Search

Collagenase Santyl

Collagenase Santyl® Ointment

250 units/g

Rx only

DESCRIPTION

Collagenase Santyl® Ointment is a sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme collagenase is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue.

CLINICAL PHARMACOLOGY

Since collagen accounts for 75% of the dry weight of skin tissue, the ability of collagenase to digest collagen in the physiological pH and temperature range makes it particularly effective in the removal of detritus.1 Collagenase thus contributes towards the formation of granulation tissue and subsequent epithelization of dermal ulcers and severely burned areas. 2, 3, 4, 5, 6 Collagen in healthy tissue or in newly formed granulation tissue is not attacked. 2, 3, 4, 5, 6, 7, 8 There is no information available on collagenase absorption through skin or its concentration in body fluids associated with therapeutic and/or toxic effects, degree of binding to plasma proteins, degree of uptake by a particular organ or in the fetus, and passage across the blood brain barrier.

INDICATIONS AND USAGE

Collagenase Santyl® Ointment is indicated for debriding chronic dermal ulcers 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and severely burned areas. 3, 4, 5, 7, 16, 19, 20, 21

CONTRAINDICATIONS

Collagenase Santyl® Ointment is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase.

PRECAUTIONS

The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme's activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. When it is suspected such materials have been used, the site should be carefully cleansed by repeated washings with normal saline before Collagenase Santyl® Ointment is applied. Soaks containing metal ions or acidic solutions should be avoided because of the metal ion and low pH. Cleansing materials such as Dakin's solution and normal saline are compatible with Collagenase Santyl® Ointment.

Debilitated patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia.

A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when Collagenase Santyl® Ointment was not confined to the wound. Therefore, the ointment should be applied carefully within the area of the wound. Safety and effectiveness in pediatric patients have not been established.

ADVERSE REACTIONS

No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. However, one case of systemic manifestations of hypersensitivity to collagenase in a patient treated for more than one year with a combination of collagenase and cortisone has been reported.

OVERDOSAGE

No systemic or local reaction attributed to overdose has been observed in clinical investigations and clinical use. If deemed necessary the enzyme may be inactivated by washing the area with povidone iodine.

DOSAGE AND ADMINISTRATION

Collagenase Santyl® Ointment should be applied once daily (or more frequently if the dressing becomes soiled, as from incontinence). When clinically indicated, crosshatching thick eschar with a #10 blade allows Collagenase Santyl® Ointment more surface contact with necrotic debris. It is also desirable to remove, with forceps and scissors, as much loosened detritus as can be done readily. Use Collagenase Santyl® Ointment in the following manner:

Prior to application the wound should be cleansed of debris and digested material by gently rubbing with a gauze pad saturated with normal saline solution, or with the desired cleansing agent compatible with Collagenase Santyl® Ointment (See PRECAUTIONS), followed by a normal saline solution rinse.

Whenever infection is present, it is desirable to use an appropriate topical antibiotic powder. The antibiotic should be applied to the wound prior to the application of Collagenase Santyl® Ointment. Should the infection not respond, therapy with Collagenase Santyl® Ointment should be discontinued until remission of the infection.

Collagenase SantyI® Ointment may be applied directly to the wound or to a sterile gauze pad which is then applied to the wound and properly secured.

Use of Collagenase Santyl® Ointment should be terminated when debridement of necrotic tissue is complete and granulation tissue is well established.

HOW SUPPLIED

Collagenase Santyl® Ointment contains 250 units of collagenase enzyme per gram of white petrolatum USP.

Do not store above 25°C (77°F). Sterility guaranteed until tube is opened.

Collagenase Santyl® Ointment is available in 15 gram and 30 gram tubes.

REFERENCES

Mandl, I., Adv Enzymol. 23:163,1961.

Boxer, A.M., Gottesman, N., Bernstein, H., & Mandl, I., Geriatrics. 24:75,1969.

Mazurek, I., Med. Welt. 22:150, 1971.

Zimmerman, WE., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 131, p. 185.

Vetra, H., & Whittaker, D., Geriatrics. 30:53, 1975.

Rao, D.B., Sane, P.G., & Georgiev, E.L., J. Am. Geriatrics Soc. 23:22, 1975.

Vrabec, R., Moserova, J., Konickova, Z., Behounkova, E., & Blaha, J., J. Hyg. Epidemiol. Microbiol. Immunol. 18:496, 1974.

Lippmann, H.I., Arch. Phys. Med. Rehabil. 54:588, 1973.

German, F.M., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 165.

Haimovici, H. & Strauch, B., in "Collagenase," Mandl, I., ed., Gordon & Breach, Science Publishers, New York, 1971, p. 177.

Lee, L.K., & Ambrus, J.L., Geriatrics. 30:91, 1975.

Locke, R.K., & Heifitz, N.M., J. Am. Pod. Assoc. 65:242, 1975.

Varma, A.O., Bugatch, E., & German, F.M., Surg. Gynecol. Obstet. 136:281, 1973.

Barrett D., Jr., & Klibanski, A., Am. J. Nurs. 73:849, 1973.

Bardfeld, L.A., J. Pod. Ed. 1:41, 1970.

Blum, G., Schweiz. Rundschau Med Praxis. 62:820,1973. Abstr. in Dermatology Digest, Feb. 1974, p. 36.

Zaruba, F., Lettl, A., Brozkova, L., Skrdlantova, H., & Krs, V., J. Hyg. Epidemiol. Microbiol. Immunol. 18:499, 1974.

Altman, M.I., Goldstein, L., & Horwitz, S., J. Am. Pod. Assoc. 68:11, 1978.

Rehn, V.J., Med. Klin. 58:799, 1963.

Krauss, H., Koslowski, L., & Zimmermann W.E., Langenbecks Arch. Klin. Chir. 303:23, 1963.

Gruenagel, H.H., Med. Klin. 58:442, 1963.

Marketed by: HEALTHPOINT®

1-800-441-8227

Healthpoint, Ltd.

Fort Worth, Texas 76107

Manufactured for DFB Biotech, Inc.

Fort Worth, Texas 76107

US Gov't License #1745

Distributed by: DPT Laboratories, Ltd.

San Antonio, Texas 78215

Reorder Nos.

0064-5010-15 (15g tube)

0064-5010-30 (30g tube)

SANTYL is a registered trademark of Healthpoint, Ltd.

129128-0809

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Collagenase Santyl
Collagenase Santyl ointment

Product Information
Product Type	HUMAN PRESCRIPTION DRUG	NDC Product Code (Source)	0064-5010
Route of Administration	TOPICAL	DEA Schedule

Active Ingredient/Active Moiety
Ingredient Name	Basis of Strength	Strength
COLLAGENASE (COLLAGENASE)	COLLAGENASE	250 U in 1 g

Inactive Ingredients
Ingredient Name	Strength
PETROLATUM

Product Characteristics
Color	WHITE (to off-white)	Score
Shape		Size
Flavor		Imprint Code
Contains

Packaging
#	NDC	Package Description	Multilevel Packaging
1	0064-5010-15	15 g In 1 TUBE	None
2	0064-5010-30	30 g In 1 TUBE	None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
BLA	BLA101995	10/18/2006

Labeler - HEALTHPOINT, LTD (965634504)

Revised: 01/2011HEALTHPOINT, LTD

More Collagenase Santyl resources

Collagenase Santyl Side Effects (in more detail)
Collagenase Santyl Use in Pregnancy & Breastfeeding
Collagenase Santyl Drug Interactions
Collagenase Santyl Support Group
0 Reviews for Collagenase Santyl - Add your own review/rating

Compare Collagenase Santyl with other medications

Actinic Keratosis

Adetide

Adetide may be available in the countries listed below.

Ingredient matches for Adetide

Adenosine Triphosphate

Adenosine Triphosphate disodium salt (a derivative of Adenosine Triphosphate) is reported as an ingredient of Adetide in the following countries:

Japan

International Drug Name Search

Somnia

Somnia may be available in the countries listed below.

Ingredient matches for Somnia

Doxylamine

Doxylamine succinate (a derivative of Doxylamine) is reported as an ingredient of Somnia in the following countries:

Taiwan

International Drug Name Search

Becantex

Becantex may be available in the countries listed below.

Ingredient matches for Becantex

Sodium Dibunate

Sodium Dibunate is reported as an ingredient of Becantex in the following countries:

Portugal

Taiwan

International Drug Name Search

Tiapaston

Tiapaston may be available in the countries listed below.

Ingredient matches for Tiapaston

Tiquizium Bromide

Tiquizium Bromide is reported as an ingredient of Tiapaston in the following countries:

Japan

International Drug Name Search

Baynas

Baynas may be available in the countries listed below.

Ingredient matches for Baynas

Ramatroban

Ramatroban is reported as an ingredient of Baynas in the following countries:

Japan

International Drug Name Search

Oxolinic Acid

In some countries, this medicine may only be approved for veterinary use.

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

J01MB05

CAS registry number (Chemical Abstracts Service)

0014698-29-4

Chemical Formula

C13-H11-N-O5

Molecular Weight

261

Therapeutic Category

Antiinfective, quinolin-derivative

Chemical Name

1,3-Dioxolo[4,5-g]quinoline-7-carboxylic acid, 5-ethyl-5,8-dihydro-8-oxo-

Foreign Names

Acidum Oxolinicum (Latin)
Oxolinsäure (German)
Acide oxolinique (French)
Ácido oxolínico (Spanish)

Generic Names

Acide oxolinique (OS: DCF)
Acido oxolinico (OS: DCIT)
Oxolinic Acid (OS: USAN, BAN)
W 4565 (IS)
Acide oxolinique (PH: Ph. Eur. 6)
Acidum oxolinicum (PH: Ph. Eur. 6)
Oxolinic Acid (PH: BP 2010, Ph. Eur. 6)
Oxolinsäure (PH: Ph. Eur. 6)
Natrium oxolinat-1-Wasser (IS)
Oxolinsäure, Natrium-1-Wasser (IS)

Brand Names

Acide oxolinique (veterinary use)
Laboratoires Franvet, France

Aqualinic (veterinary use)
Vetrepharm, United Kingdom

Aquinox (veterinary use)
Cypharm, Ireland; Vericor, United Kingdom

Cofamix Acide Oxolinique (veterinary use)
Coophavet, France

Concentrat (veterinary use)
Sogeval, France

Inoxyl (veterinary use)
Arovet, Switzerland; Iberil, Portugal; Inovet, Netherlands

Oxolin
Stada, Latvia

Oxolini
GAMA, Georgia

Oxolinsyre (veterinary use)
Skretting Vet, Norway

Oxomid (veterinary use)
Virbac, France

Cofoxyl (veterinary use)
Coophavet, France

Inoxyl (veterinary use)
Laboratoires Biové, France

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
DCIT	Denominazione Comune Italiana
IS	Inofficial Synonym
OS	Official Synonym
PH	Pharmacopoeia Name
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name

Click for further information on drug naming conventions and International Nonproprietary Names.

Smoothie Readi-Cat 2 oral and rectal

Generic Name: barium sulfate (oral and rectal) (BER ee um SUL fate)

Brand Names: Anatrast, Bar-Test, Baricon, Baro-Cat, Barosperse, Bear-E-Yum GI, CheeTah, CheeTah Butterscotch, CheeTah Chocolaty-Fudge, CheeTah Orange, CheeTah Raspberry, Digibar 190, E-Z AC, E-Z Disk, E-Z Dose Kit with Polibar Plus, E-Z Paste, E-Z-Cat, E-Z-Cat Dry, E-Z-HD, E-Z-Paque, Enecat, Eneset 2, Enhancer, Entero VU, Entero-H, Entrobar, Esopho-Cat, Intropaste, Liqui-Coat HD, Liquid Barosperse, Liquid E-Z Paque, Liquid Polibar, Liquid Polibar Plus, Maxibar, Medebar Plus, Medebar Super 250, Polibar ACB, Readi-Cat, Readi-Cat 2, Scan C, Sitzmarks, Smoothie Readi-Cat 2, Sol-O-Pake, Tagitol V, Tonojug, Tonopaque, Varibar Honey, Varibar Nectar, Varibar Pudding, Varibar Thin, Varibar Thin Honey, Volumen

What is barium sulfate?

Barium sulfate is in a group of drugs called contrast agents. Barium sulfate works by coating the inside of your esophagus, stomach, or intestines which allows them to be seen more clearly on a CT scan or other radiologic (x-ray) examination.

Barium sulfate is used to help diagnose certain disorders of the esophagus, stomach, or intestines.

Barium sulfate may also be used for purposes not listed in this medication guide.

What is the most important information I should know about barium sulfate?

You should not use this medication if you are allergic to barium sulfate. Tell your doctor if you have ever had an allergic reaction to a contrast agent.

Before you use barium sulfate, tell your doctor if you have any allergies, or if you have asthma, cystic fibrosis, heart disease or high blood pressure, rectal cancer, a colostomy, a blockage in your stomach or intestines, a condition called pseudotumor cerebri, or if you have recently had a rectal biopsy or surgery on your esophagus, stomach, or intestines.

Tell your doctor if you are pregnant or breast-feeding before your medical test.

Carefully follow your doctor's instructions about what to eat or drink within the 24-hour period before your test.

Serious side effects of barium sulfate may include severe stomach pain, sweating, ringing in your ears, pale skin, weakness, or severe cramping, diarrhea, or constipation

What should I discuss with my health care provider before using barium sulfate?

You should not use barium sulfate if you are allergic to it. Tell your doctor if you have ever had an allergic reaction to a contrast agent.

To make sure you can safely use barium sulfate, tell your doctor if you have any of these other conditions:

asthma, eczema, or allergies;

a blockage in your stomach or intestines;

cystic fibrosis;

a colostomy;

rectal cancer;

heart disease or high blood pressure;

Hirschsprung's disease (a disorder of the intestines);

a condition called pseudotumor cerebri (high pressure inside the skull that may cause headaches, vision loss, or other symptoms);

a recent history of surgery on your esophagus, stomach, or intestines;

a history of perforation (a hole or tear) in your esophagus, stomach, or intestines;

if you have recently had a rectal biopsy;

if you have ever choked on food by accidentally inhaling it into your lungs;

if you are allergic to simethicone (Gas-X, Phazyme, and others); or

if you are allergic to latex rubber.

It is not known whether barium sulfate will harm an unborn baby, but the radiation used in x-rays and CT scans may be harmful. Before your medical test, tell your doctor if you are pregnant. Barium sulfate may pass into breast milk and could harm a nursing baby. Before your medical test, tell your doctor if you are breast-feeding a baby.

How should I use barium sulfate?

Use this medication exactly as prescribed by your doctor. Do not use it in larger amounts or for longer than recommended.

Barium sulfate comes in tablets, paste, cream, or liquid forms.

In some cases, barium sulfate is taken by mouth. The liquid form may also be used as a rectal enema.

You may need to begin using this medication at home a day before your medical test. Follow your doctor's instructions about how much of the medication to use and how often.

If you are receiving barium sulfate as a rectal enema, a healthcare professional will give you the medication at the clinic or hospital where your testing will take place.

Do not crush, chew, or break a barium sulfate tablet. Swallow the pill whole.

Dissolve the barium sulfate powder in a small amount of water. Stir this mixture and drink all of it right away. To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.

If you receive the medication as a liquid to take by mouth, shake the liquid well just before you measure a dose. To be sure you get the correct dose, measure the liquid with a marked measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.

Carefully follow your doctor's instructions about what to eat or drink within the 24-hour period before your test.

Store at room temperature away from heat and moisture. Keep the bottle tightly closed when not in use.

What happens if I miss a dose?

If you are using barium sulfate at home, call your doctor for instructions if you miss a dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include severe stomach pain, ongoing diarrhea, confusion, or weakness.

What should I avoid before or after using barium sulfate?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

Barium sulfate side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have a serious side effect such as:

severe stomach pain;

severe cramping, diarrhea, or constipation;

sweating;

ringing in your ears;

confusion, fast heart rate; or

pale skin, weakness.

Less serious side effects may include:

mild stomach cramps;

nausea, vomiting;

loose stools or mild constipation.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect barium sulfate?

There may be other drugs that can interact with barium sulfate. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

Compare Smoothie Readi-Cat 2 with other medications

Computed Tomography

Where can I get more information?

Your doctor or pharmacist can provide more information about barium sulfate.

See also: Smoothie Readi-Cat 2 side effects (in more detail)

Infectious Posterior Uveitis Medications

There are currently no drugs listed for "Infectious Posterior Uveitis".

Learn more about Infectious Posterior Uveitis

Micromedex Care Notes:

Histoplasmosis
Syphilis

Medical Encyclopedia:

Histoplasmosis
Syphilis
Toxoplasmosis

Drug List:

Thursday, September 29, 2016

Eetless

Eetless may be available in the countries listed below.

Ingredient matches for Eetless

Cathine

Cathine hydrochloride (a derivative of Cathine) is reported as an ingredient of Eetless in the following countries:

South Africa

International Drug Name Search

Bradoral

Bradoral may be available in the countries listed below.

Ingredient matches for Bradoral

Domiphen Bromide

Domiphen Bromide is reported as an ingredient of Bradoral in the following countries:

Italy

Taiwan

International Drug Name Search

Bactrimel

Bactrimel may be available in the countries listed below.

Ingredient matches for Bactrimel

Sulfamethoxazole

Sulfamethoxazole is reported as an ingredient of Bactrimel in the following countries:

Chile

Greece

Netherlands

Venezuela

Trimethoprim

Trimethoprim is reported as an ingredient of Bactrimel in the following countries:

Chile

Greece

Netherlands

Venezuela

International Drug Name Search

Estreptomicina

Estreptomicina may be available in the countries listed below.

Ingredient matches for Estreptomicina

Streptomycin

Streptomycin sulfate (a derivative of Streptomycin) is reported as an ingredient of Estreptomicina in the following countries:

Argentina

Chile

Peru

International Drug Name Search

Zonalon Cream

Pronunciation: DOX-e-pin
Generic Name: Doxepin
Brand Name: Zonalon

Zonalon Cream is used for:

Relieving moderate itching caused by certain skin conditions.

Zonalon Cream is an antipruritic cream. It is not known exactly how it works. It may block histamine to relieve itching.

Do NOT use Zonalon Cream if:

you are allergic to any ingredient in Zonalon Cream

you have certain prostate problems (eg, asymptomatic prostatic hypertrophy), uncontrolled glaucoma, or trouble urinating (urinary retention)

you are taking clonidine, an H₁ antagonist (eg, astemizole, terfenadine), or ibutilide

you have taken linezolid, methylene blue, or a monoamine oxidase inhibitor (MAOI) (eg, furazolidone, phenelzine, isocarboxazid) within the past 14 days

Contact your doctor or health care provider right away if any of these apply to you.

Before using Zonalon Cream:

Some medical conditions may interact with Zonalon Cream. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have a history of heart problems, seizures (eg, epilepsy), overactive thyroid, glaucoma or increased pressure in the eyes, prostate problems (eg, benign prostatic hypertrophy [BPH]), certain blood problems (eg, porphyria), suicidal thoughts or attempts, or a history of alcohol abuse

Some MEDICINES MAY INTERACT with Zonalon Cream. Tell your health care provider if you are taking any other medicines, especially any of the following:

Antiarrhythmics (eg, quinidine, propafenone, flecainide), antifungal medicines (eg, fluconazole, terbinafine), carbamazepine, cimetidine, mibefradil, phenothiazines (eg, chlorpromazine, thioridazine), or selective serotonin reuptake inhibitors (SSRIs) (eg, fluoxetine, sertraline) because they may increase the risk of Zonalon Cream's side effects

Anticoagulants (eg, warfarin), clonidine, guanadrel, H₁ antagonists (eg, astemizole, terfenadine), ibutilide, sulfonylureas (eg, tolazamide, glipizide), sympathomimetics (eg, phenylephrine, pseudoephedrine), or tramadol because the risk of their side effects may be increased by Zonalon Cream

Clonidine, guanadrel, guanethidine, or guanfacine because their effectiveness may be decreased by Zonalon Cream

Linezolid, MAOIs (eg, furazolidone, phenelzine, isocarboxazid), or methylene blue because severe toxic effects may occur

This may not be a complete list of all interactions that may occur. Ask your health care provider if Zonalon Cream may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Zonalon Cream:

Use Zonalon Cream as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Zonalon Cream is for external use only.

Wash and completely dry the affected area. Apply a thin film to the affected area and gently rub it in.

Wash your hands immediately after using Zonalon Cream, unless they are part of the treated area.

Do not bandage or otherwise cover the treated area unless directed to do so by your doctor. Avoid tight-fitting clothes on the treated area.

If you miss a dose of Zonalon Cream, use it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule.

Ask your health care provider any questions you may have about how to use Zonalon Cream.

Important safety information:

Zonalon Cream may cause drowsiness. This effect may be worse if you take it with alcohol or certain medicines. Use Zonalon Cream with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

Zonalon Cream will add to the effects of alcohol and other depressants. Ask your pharmacist if you have questions about which medicines are depressants.

Limit your alcohol consumption while taking Zonalon Cream.

Avoid getting Zonalon Cream in your eyes or on the inside of your nose or mouth.

Use Zonalon Cream with caution in the ELDERLY; they may be more sensitive to its effects, especially drowsiness and confusion.

Zonalon Cream should not be used in CHILDREN; safety and effectiveness in children have not been confirmed.

PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Zonalon Cream while you are pregnant. It is not known if Zonalon Cream is found in breast milk. Do not breast-feed while taking Zonalon Cream.

Possible side effects of Zonalon Cream:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Abnormal skin sensations; burning and stinging at the application site; changes in emotions; confusion; dizziness; drowsiness; dry and tight skin; dry mouth and lips; fatigue; headache; itching; swelling; taste changes; thirst.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); blurred vision; rapid or pounding heartbeat; severe burning and stinging at the application site.

This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.

See also: Zonalon side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Zonalon Cream may be harmful if swallowed.

Proper storage of Zonalon Cream:

Store Zonalon Cream at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Zonalon Cream out of the reach of children and away from pets.

General information:

If you have any questions about Zonalon Cream, please talk with your doctor, pharmacist, or other health care provider.

Zonalon Cream is to be used only by the patient for whom it is prescribed. Do not share it with other people.

If your symptoms do not improve or if they become worse, check with your doctor.

Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Zonalon Cream. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

More Zonalon resources

Zonalon Side Effects (in more detail)
Zonalon Use in Pregnancy & Breastfeeding
Zonalon Drug Interactions
Zonalon Support Group
0 Reviews for Zonalon - Add your own review/rating

Compare Zonalon with other medications

Atopic Dermatitis
Dermatitis
Eczema
Lichen Simplex Chronicus
Pruritus

Wednesday, September 28, 2016

aztreonam inhalation

Generic Name: aztreonam (inhalation) (AZ tree oh nam)

Brand Names: Cayston

What is aztreonam?

Aztreonam is an antibiotic that fights severe or life-threatening infection caused by bacteria.

Aztreonam inhalation is used to improve breathing symptoms in people who have cystic fibrosis and a certain bacteria in their lungs. This medication is for use in adults and children who are at least 7 years old.

Aztreonam may also be used for purposes not listed in this medication guide.

What is the most important information I should know about aztreonam?

You should not use this medication if you are allergic to aztreonam.

Before using aztreonam, tell your doctor if you are allergic to any type of antibiotic, especially a cephalosporin (Ceftin, Cefzil, Keflex, Omnicef, and others), a penicillin (Amoxil, Augmentin, Bactocill, Bicillin C-R, Dycill, Dynapen, Omnipen, Principen, PC Pen VK, Pen-V, Pfizerpen, and others), or similar antibiotics such as Invanz, Primaxin, or Marum.

Use aztreonam for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Aztreonam will not treat a viral infection such as the common cold or flu.

Aztreonam inhalation should be used only with an Altera brand nebulizer. Do not use any other type of nebulizer or inhaler device with this medication. Do not mix other medicines with aztreonam in the nebulizer. If you use other inhaled medications, you may need to use them in a certain order while using aztreonam inhalation. Ask your doctor for specific instructions about when to use your other medications in relation to your aztreonam inhalation doses.

What should I discuss with my health care provider before using aztreonam?

You should not use this medication if you are allergic to aztreonam.

Before using aztreonam, tell your doctor if you are allergic to any type of antibiotic, especially:

cephalosporins such as cefdinir (Omnicef), cefprozil (Cefzil), cefuroxime (Ceftin), cephalexin (Keflex), and others;

penicillins such as amoxicillin (Amoxil, Augmentin), ampicillin (Omnipen, Principen), dicloxacillin (Dycill, Dynapen), oxacillin (Bactocill), or penicillin (Bicillin C-R, PC Pen VK, Pen-V, Pfizerpen), and others; or

similar antibiotics such as ertapenem (Invanz), imipenem (Primaxin), or meropenem (Merrem).

If you have kidney disease, you may need an aztreonam dose adjustment or special tests. FDA pregnancy category B. Aztreonam is not expected to harm an unborn baby. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Aztreonam can pass into breast milk and may harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

How should I use aztreonam?

Use exactly as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Follow the directions on your prescription label.

This medication comes with patient instructions for safe and effective use. Follow these directions carefully. Ask your doctor or pharmacist if you have any questions.

Astreonam inhalation is a powder medicine that must be mixed with a liquid (diluent) just before using it. Be sure you understand how to properly mix the medication before pouring it into the nebulizer.

Prepare aztreonam in the nebulizer only when you are ready to give yourself a dose. Swirl the mixture gently until the powder has dissolved, then pour the mixture into the handset of the nebulizer. Use the medicine right away after placing it in the nebulizer. Do not save it for later use.

Do not use the medication if it looks cloudy or has particles in it. Call your doctor for a new prescription.

Each vial (bottle) of aztreonam and each ampule of diluent are for one use only. Throw away the empty bottle and ampule after mixing one dose, even if there is diluent left in the ampule.

Aztreonam inhalation is usually given 3 times daily for 28 days. Follow your doctor's dosing instructions very carefully. Your doses should be spaced at least 4 hours apart.

You may need to use a bronchodilator medication before each dose of aztreonam inhalation. Follow your doctor's instructions about the type of bronchodilator to use and when to use it.

Use aztreonam for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared. Aztreonam will not treat a viral infection such as the common cold or flu.

Do not give this medication to another person, even if they have the same symptoms you have. Store the powder and diluent in the refrigerator, do not freeze. After taking the powder and diluent out of the refrigerator, you may store them at room temperature away from moisture, heat, and light. This medicine must be used within 28 days if you keep it at room temperature.

What happens if I miss a dose?

Use the missed dose as soon as you remember. Then wait at least 4 hours before using your next dose. Even if you miss a dose, you should still try to get all of your scheduled doses for the day, as long as they are spaced at least 4 hours apart. Do not use two doses at one time or use extra medicine to make up a missed dose.

What happens if I overdose?

Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while using aztreonam?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

Aztreonam side effects

bronchospasm (wheezing, chest tightness, trouble breathing) right after using the medicine; or

any new or worsening symptoms.

Less serious side effects may include:

mild stomach discomfort, vomiting;

cough, sore throat;

stuffy nose; or

low fever.

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

Aztreonam Dosing Information

Usual Adult Dose for Bacteremia:

2 g IV every 6 to 8 hours

Therapy should be continued for approximately 10 to 14 days, depending on the nature and severity of the infection.

Usual Adult Dose for Bacterial Infection:

Moderately severe infections: 1 to 2 g IV or IM every 8 to 12 hours
Severe infections: 2 g IV every 6 to 8 hours (maximum, 8 g/day)

Usual Adult Dose for Cystic Fibrosis:

Inhalation:
Initial dose: 75 mg via nebulizer over approximately 2 to 3 minutes 3 times a day for 28 days; doses should be at least 4 hours apart

Maintenance dose: Administer in alternating cycles of 28 days on and 28 days off.

For patients on multiple inhaled therapies, the following order of administration is recommended: bronchodilator, mucolytics, and lastly, aztreonam for inhalation.

Usual Adult Dose for Febrile Neutropenia:

2 g IV every 6 to 8 hours

Therapy should be continued until the absolute neutrophil count is greater than 500/mm3 and no infection is found or until an adequate clinical response is achieved if a susceptible infection is found and the patient has been afebrile for at least 24 hours. Therapy for neutropenic patients is often required for up to 3 weeks.

Usual Adult Dose for Intraabdominal Infection:

1 to 2 g IV every 8 or 12 hours

For severe or life-threatening infections, a dose of 2 g IV every 6 to 8 hours is recommended. Therapy should be continued for approximately 10 to 14 days, depending on the nature and severity of the infection.

Usual Adult Dose for Peritonitis:

Usual Adult Dose for Osteomyelitis:

1 to 2 g IV every 8 or 12 hours

For severe or life-threatening infections, a dose of 2 g IV every 6 to 8 hours is recommended. Therapy should be continued for approximately 4 to 6 weeks, depending on the nature and severity of the infection. Chronic osteomyelitis may require an additional 2 months of oral antibiotics.

Usual Adult Dose for Pelvic Inflammatory Disease:

1 to 2 g IV every 8 or 12 hours

For severe or life-threatening infections, a dose of 2 g IV every 6 to 8 hours is recommended. Therapy should be continued until this patient is afebrile and pain-free for 24 to 36 hours.

Usual Adult Dose for Pneumonia:

1 to 2 g IV every 8 or 12 hours

For severe or life-threatening infections, a dose of 2 g IV every 6 to 8 hours is recommended. Therapy should be continued for approximately 21 days, depending on the nature and severity of the infection.

Usual Adult Dose for Pyelonephritis:

1 to 2 g IV every 8 or 12 hours

For severe or life-threatening infections, a dose of 2 g IV every 6 to 8 hours is recommended. Therapy should be continued for approximately 14 days, depending on the nature and severity of the infection.

Usual Adult Dose for Skin or Soft Tissue Infection:

1 to 2 g IV every 8 or 12 hours

For severe or life-threatening infections, a dose of 2 g IV every 6 to 8 hours is recommended. Therapy should be continued for approximately 7 days or until 3 days after acute inflammation disappears. For more severe infections, such as diabetic soft tissue infections, 14 to 21 days of therapy may be required.

Usual Adult Dose for Urinary Tract Infection:

500 mg to 1 g IV or IM every 8 to 12 hours

Usual Pediatric Dose for Intraabdominal Infection:

7 days or less, 2000 g or less: 30 mg/kg IV every 12 hours
7 days or less, 2001 g or more: 30 mg/kg IV every 8 hours

8 to 30 days, 1199 g or less: 30 mg/kg IV every 12 hours
8 to 30 days, 1200 to 2000 g: 30 mg/kg IV every 8 hours
8 to 30 days, 2001 g or more: 30 mg/kg IV every 6 hours

1 month to 18 years: 30 mg/kg IV every 6 to 8 hours, up to a maximum of 2 g/dose or 8 g/day

Usual Pediatric Dose for Pneumonia:

Usual Pediatric Dose for Bacterial Infection:

Usual Pediatric Dose for Urinary Tract Infection:

Usual Pediatric Dose for Skin and Structure Infection:

Usual Pediatric Dose for Cystic Fibrosis:

Inhalation:
7 years or older:
Initial dose: 75 mg via nebulizer over approximately 2 to 3 minutes 3 times a day for 28 days; doses should be at least 4 hours apart

Maintenance dose: Administer in alternating cycles of 28 days on and 28 days off.

For patients on multiple inhaled therapies, the following order of administration is recommended: bronchodilator, mucolytics, and lastly, aztreonam for inhalation.

What other drugs will affect aztreonam?

If you use other inhaled medications, you may need to use them in a certain order while using aztreonam inhalation. Ask your doctor for specific instructions about when to use your other medications in relation to your aztreonam inhalation doses.

There may be other drugs that can interact with aztreonam. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.

More aztreonam resources

Aztreonam Side Effects (in more detail)
Aztreonam Use in Pregnancy & Breastfeeding
Aztreonam Drug Interactions
Aztreonam Support Group
0 Reviews for Aztreonam - Add your own review/rating

Compare aztreonam with other medications

Bacteremia
Bacterial Infection
Bone infection
Cystic Fibrosis
Febrile Neutropenia
Intraabdominal Infection
Kidney Infections
Pelvic Inflammatory Disease
Peritonitis
Pneumonia
Pneumonia with Cystic Fibrosis
Skin and Structure Infection
Skin Infection
Urinary Tract Infection

Where can I get more information?

Your doctor or pharmacist can provide more information about aztreonam inhalation.

See also: aztreonam side effects (in more detail)

Raltegravir Potassium

Class: Integrase Inhibitors
Chemical Name: N - [(4 - Fluorophenyl)methyl] - 1,6 - dihydro - 5 - hydroxy - 1 - methyl - 2 - {1 - methyl - 1 - [[(5 - methyl - 1,3,4 - oxadiazol - 2 - yl)carbonyl]amino]ethyl} - 6 - oxo - 4 - pyrimidinecarboxamide monopotassium salt
Molecular Formula: C₂₀H₂₀FKN₆O₅
CAS Number: 871038-72-1
Brands: Isentress

Introduction

Antiretroviral; HIV integrase inhibitor.¹ ² ³ ⁴ ⁵

Uses for Raltegravir Potassium

Treatment of HIV Infection

Treatment of HIV-1 infection in conjunction with other antiretrovirals.¹ ⁸ ¹⁴

Safety and efficacy not established in pediatric patients <16 years of age.¹ ¹³

Raltegravir Potassium Dosage and Administration

Administration

Oral Administration

Administer orally¹ without regard to food.¹ ⁵

Dosage

Available as raltegravir potassium; dosage expressed in terms of raltegravir.¹

If used with rifampin, dosage adjustment of raltegravir is necessary.¹

Must be given in conjunction with other antiretrovirals.¹

Pediatric Patients

Treatment of HIV Infection

Oral

Adolescents ≥16 years of age: 400 mg twice daily.¹

Adolescents ≥16 years of age receiving rifampin concomitantly 800 mg twice daily.¹

Adults

Treatment of HIV Infection

Oral

400 mg twice daily.¹ ⁵

Adults receiving rifampin: 800 mg twice daily.¹

Special Populations

Hepatic Impairment

Dosage adjustment not necessary in patients with mild to moderate hepatic impairment;¹ ⁵ data not available in patients with severe hepatic impairment.¹ (See Hepatic Impairment under Cautions.)

Renal Impairment

Dosage adjustment not necessary.¹ ⁵ Avoid administering drug before dialysis session.¹ (See Renal Impairment under Cautions.)

Geriatric Patients

Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.¹

Cautions for Raltegravir Potassium

Contraindications

Manufacturer states none known.¹

Warnings/Precautions

Immune Reconstitution Syndrome

During initial treatment, patients who respond to antiretroviral therapy may develop an inflammatory response to indolent or residual opportunistic infections (e.g., Mycobacterium avium complex [MAC], M. tuberculosis, cytomegalovirus [CMV], Pneumocystis jiroveci [formerly P. carinii], varicella-zoster virus [VZV]); this may necessitate further evaluation and treatment.¹

Interactions

Concomitant use with drugs that are potent inducers of uridine diphosphate-glucuronosyltransferase (UGT) 1A1 (e.g., rifampin) may result in decreased plasma concentrations of raltegravir.¹ (See Interactions and see Dosage and Administration.)

Sensitivity Reactions

Hypersensitivity Reactions

Hypersensitivity reactions (e.g., diffuse rash with fever, facial edema) reported.¹ ^b

Musculoskeletal Effects

Increased serum CK concentrations observed.¹

Myopathy and rhabdomyolysis reported rarely; relationship to drug not known.¹ Use caution in patients at increased risk of myopathy or rhabdomyolysis, including those receiving concomitant therapy with a drug associated with myopathy or rhabdomyolysis.¹

Specific Populations

Pregnancy

Category C.¹

Antiretroviral Pregnancy Registry at 800-258-4263.¹

Some experts state that safety and pharmacokinetic data are insufficient to recommend raltegravir in pregnant women.⁷

Lactation

Distributed into milk in rats; not known whether distributed into human milk.¹

Instruct HIV-infected women not to breast-feed because of risk of HIV transmission and risk of adverse effects in the infant.¹ ⁵ ⁷

Pediatric Use

Safety and efficacy not established in pediatric patients <16 years of age.¹ ¹³

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults.¹

Use with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.¹

Hepatic Impairment

Risk for further elevations in hepatic enzyme concentrations in patients with chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.¹ (See Hepatic Impairment under Dosage and Administration.)

Renal Impairment

Not known if removed by dialysis; avoid administering drug before dialysis session.¹ (See Renal Impairment under Dosage and Administration.)

Common Adverse Effects

Insomnia, headache, nausea, asthenia, fatigue.¹

Interactions for Raltegravir Potassium

Metabolized by UGT 1A1.¹ Does not inhibit UGT 1A1 or UGT 2B7 in vitro.¹

Not a substrate for CYP isoenzymes.¹ Does not inhibit CYP isoenzymes 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A or induce CYP1A2, 2B6, or 3A4.¹

Does not inhibit P-glycoprotein-mediated transport.¹

Drugs Affecting or Metabolized by Uridine Diphosphate-glucuronosyltransferase 1A1

Potential pharmacokinetic interactions with drugs that are potent inducers of UGT 1A1 (decreased plasma concentrations of raltegravir)¹ ⁵ or inhibitors of UGT 1A1 (increased plasma concentrations of raltegravir).¹

Not expected to affect pharmacokinetics of drugs that are substrates for UGT 1A1 or UGT 2B7.¹

Drugs Affecting or Metabolized by Hepatic Microsomal Enzymes

Pharmacokinetic interactions unlikely with drugs that are substrates for CYP isoenzymes 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A.¹

Drugs Metabolized by P-Glycoprotein Transport System

Pharmacokinetic interactions unlikely with drugs that are substrates for P-glycoprotein.¹

Specific Drugs

Drug	Interaction	Comments
Abacavir	In vitro evidence of additive to synergistic antiretroviral effects¹
Amprenavir	In vitro evidence of additive to synergistic antiretroviral effects¹
Anticonvulsants (phenobarbital, phenytoin)	Phenytoin and/or phenobarbital potentially may affect the UGT 1A1 pathway;¹¹ effect on raltegravir pharmacokinetics unknown¹	Concomitant use of phenytoin and/or phenobarbital prohibited in expanded-access program¹¹
Antimycobacterials, rifamycins (rifabutin, rifampin, rifapentine)	Rifabutin: Possible decreased raltegravir concentrations⁵ Rifampin: Decreased peak plasma concentrations and AUC of raltegravir¹ ⁵ ¹¹	Rifabutin: Consider possibility of pharmacokinetic interaction if optimal virologic response not achieved⁵ Rifampin: Dosage adjustment needed of raltegravir; use raltegravir 800 mg twice daily¹ Rifapentine: Concomitant use not recommended⁵
Atazanavir	Atazanavir or ritonavir-boosted atazanavir: Increased raltegravir concentrations;¹ clinical importance unknown; however, combination of ritonavir-boosted atazanavir and raltegravir reportedly well tolerated¹ ¹¹ In vitro evidence of additive to synergistic antiretroviral effects¹	Ritonavir-boosted atazanavir: Dosage adjustment of raltegravir not needed¹
Benzodiazepines (e.g., midazolam)	Raltegravir not expected to affect pharmacokinetics of midazolam ¹ ¹⁰
Delavirdine	In vitro evidence of additive to synergistic antiretroviral effects¹
Didanosine	In vitro evidence of additive to synergistic antiretroviral effects¹
Efavirenz	Decreased raltegravir concentrations;¹ ¹¹ clinical importance unknown¹¹ In vitro evidence of additive to synergistic antiretroviral effects¹	Consider possibility of a pharmacokinetic interaction if optimal virologic response not achieved⁵
Enfuvirtide	In vitro evidence of additive to synergistic antiretroviral effects¹
Etravirine	Decreased raltegravir concentrations; no change in etravirine concentrations. Clinical importance unknown¹
Hormonal contraceptives	Raltegravir not expected to affect pharmacokinetics of hormonal contraceptives¹
Indinavir	In vitro evidence of additive to synergistic antiretroviral effects¹
Lamivudine	Raltegravir not observed to have a clinically meaningful effect on pharmacokinetics of lamivudine¹ In vitro evidence of additive to synergistic antiretroviral effects¹
Lopinavir	In vitro evidence of additive to synergistic antiretroviral effects¹
Methadone	Raltegravir not expected to affect pharmacokinetics of methadone¹
Nelfinavir	In vitro evidence of additive to synergistic antiretroviral effects¹
Nevirapine	In vitro evidence of additive to synergistic antiretroviral effects¹
Omeprazole	Increased raltegravir concentrations¹	Dosage adjustment not necessary¹
Ritonavir	Pharmacokinetic interaction with low-dose ritonavir unlikely¹¹ In vitro evidence of additive to synergistic antiretroviral effects¹	Consider possibility of drug interactions between raltegravir and other protease inhibitors (PIs) when low-dose ritonavir is used to boost PI concentrations¹¹
Saquinavir	In vitro evidence of additive to synergistic antiretroviral effects¹
Stavudine	In vitro evidence of additive to synergistic antiretroviral effects¹
Tenofovir	Increased raltegravir concentrations; no change in concentrations of tenofovir¹ In vitro evidence of additive to synergistic antiretroviral effects¹
Tipranavir	Ritonavir-boosted tipranavir: Decreased raltegravir concentrations; however, no effect on efficacy of raltegravir observed in small study¹	Ritonavir-boosted tipranavir: Dosage adjustment of raltegravir not needed¹ Consider possibility of pharmacokinetic interaction if optimal virologic response not achieved⁵
Zidovudine	In vitro evidence of additive to synergistic antiretroviral effects¹

Raltegravir Potassium Pharmacokinetics

Absorption

Bioavailability

Absolute bioavailability not established.¹

Following oral administration in the fasted state, peak plasma concentrations attained in approximately 3 hours.¹

Food

AUC increased by approximately 13% when administered with a moderate-fat meal compared with administration in the fasting state.¹

Distribution

Extent

Distributed into milk in rats; not known whether distributed into human milk.¹

Not known whether crosses the placenta.¹

Plasma Protein Binding

83%.¹

Elimination

Metabolism

Metabolized mainly by UGT 1A1-mediated glucuronidation in the liver.¹ ⁵

Elimination Route

Excreted in feces (51%) and urine (32%).¹

Not known if removed by dialysis.¹

Half-life

9 hours.¹

Special Populations

Moderate hepatic impairment: No clinically important pharmacokinetic differences between patients with moderate hepatic impairment and healthy individuals observed.¹

Severe hepatic impairment: Pharmacokinetics not studied.¹

Severe renal impairment: No clinically important pharmacokinetic differences between patients with severe renal impairment and healthy individuals observed.¹

Pediatric patients: Pharmacokinetics not established.¹

Stability

Storage

Oral

Tablets

20–25°C (may be exposed to 15–30°C).¹

ActionsActions

Inhibits catalytic activity of HIV-1 integrase, an enzyme that integrates HIV DNA into the host cell genome.¹ ⁴

Inhibition of integrase prevents propagation of viral infection.¹ ⁴

Active against some strains of HIV-1 resistant to nucleoside reverse transcriptase inhibitors (NRTIs) and PIs.¹

Resistant HIV-1 strains have been produced in vitro and have emerged during raltegravir therapy.¹ ^b

Advice to Patients

Critical nature of compliance with HIV therapy.¹ Used in conjunction with other antiretrovirals; do not use for monotherapy.¹

Antiretroviral therapy is not a cure for HIV infection, and opportunistic infections still may occur.¹ HIV transmission via sexual contact or sharing needles is not prevented by antiretrovirals.¹

Importance of reading patient information provided by the manufacturer.¹

Importance of informing clinician if unusual symptoms (e.g., muscle pain, tenderness, weakness) develop or known symptoms persist or worsen.¹

If a dose is missed, administer as soon as it is remembered; however, if a dose is skipped, a double dose should not be taken to make up for the missed dose.¹

Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and herbal products, and any concomitant illnesses (e.g., chronic HBV or HCV).¹

Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.¹

Importance of advising patients of other important precautionary information.¹ (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Raltegravir Potassium
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Tablet, film-coated	400 mg (of raltegravir)	Isentress	Merck

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Isentress 400MG Tablets (MERCK SHARP & DOHME): 60/$994.9 or 180/$2874.45

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

References

1. Merck. Isentress (raltegravir) tablets prescribing information. Whitehouse Station, NJ; 2009 Jul.

2. Cooper D, Gatell J, Rockstroh J et al. Results of BENCHMRK-1, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA. 2007 Feb 25-28. Abstract 105aLB. From website.

3. Steigbigel R, Kumar P, Eron J et al. Results of BENCHMRK-2, a phase III study evaluating the efficacy and safety of MK-0518, a novel HIV-1 integrase inhibitor, in patients with triple-class resistant virus. 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA. 2007 Feb 25-28. Abstract 105bLB. From website.

4. Grinsztejn B, Nguyen BY, Katlama C et al for Protocol 005 team. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007; 369:1261-9. [PubMed 17434401]

5. Panel on Antiretroviral Guidelines for Adults and Adolescents of the Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (November 3, 2008). From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website.

6. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society–USA panel. JAMA. 2006; 296:827-43. [PubMed 16905788]

7. Perinatal HIV Guidelines Working Group. Public Health Service task force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States (April 29, 2009). From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website.

8. Markowitz M, Nguyen BY, Gotuzzo E et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr. 2007; 46:125-33. [PubMed 17721395]

9. Anon. Two new drugs for HIV infection. Med Lett Drugs Ther. 2008; 50:2-4.

10. Iwamoto M, Kassahun K, Troyer MD et al. Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation. J Clin Pharmacol. 2008; 48:209-14. [PubMed 18077730]

11. Correll T, Klibanov OM. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy. 2008: 28:90-101.

12. Merck, North Wales, Pa. Personal communication.

13. Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children of the National Resource Center at the François-Xavier Bagnoud Center, Health Resources and Services Administration (HRSA), and National Institutes of Health (NIH). Guidelines for the use of antiretroviral agents in pediatric HIV infection (February 23, 2009). From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website.

14. Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008; 359:339-54. [PubMed 18650512]

b. Merck, North Wales, PA: Personal communication.

More Raltegravir Potassium resources

Raltegravir Potassium Side Effects (in more detail)
Raltegravir Potassium Dosage
Raltegravir Potassium Use in Pregnancy & Breastfeeding
Raltegravir Potassium Drug Interactions
Raltegravir Potassium Support Group
5 Reviews for Raltegravir Potassium - Add your own review/rating

Compare Raltegravir Potassium with other medications

HIV Infection

Vomec

Vomec may be available in the countries listed below.

Ingredient matches for Vomec

Meclozine

Meclozine dihydrochloride (a derivative of Meclozine) is reported as an ingredient of Vomec in the following countries:

Bangladesh

International Drug Name Search

Dimetapp Decongestant Drops

Pronunciation: FEN-il-EF-rin
Generic Name: Phenylephrine
Brand Name: Examples include Dimetapp Decongestant and Little Colds Decongestant

Dimetapp Decongestant Drops are used for:

Relieving congestion due to colds, flu, and allergies. It may also be used for other conditions as determined by your doctor.

Dimetapp Decongestant Drops are a decongestant. It works by reducing swelling and constricting blood vessels in the nasal passages, allowing you to breathe more easily.

Do NOT use Dimetapp Decongestant Drops if:

you are allergic to any ingredient in Dimetapp Decongestant Drops

you are taking furazolidone or have taken a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) in the last 14 days

you have high blood pressure or an abnormally fast heartbeat

Contact your doctor or health care provider right away if any of these apply to you.

Before using Dimetapp Decongestant Drops:

Some medical conditions may interact with Dimetapp Decongestant Drops. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:

if you are pregnant, planning to become pregnant, or are breast-feeding

if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

if you have allergies to medicines, foods, or other substances

if you have heart disease, diabetes, phenylketonuria (PKU), an adrenal gland tumor, or thyroid disease

Some MEDICINES MAY INTERACT with Dimetapp Decongestant Drops. Tell your health care provider if you are taking any other medicines, especially any of the following:

Rauwolfia derivatives (eg, reserpine) or tricyclic antidepressants (eg, amitriptyline) because they may decrease Dimetapp Decongestant Drops's effectiveness

Cocaine, furazolidone, MAOIs (eg, phenelzine), methyldopa, oxytocic medicines (eg, oxytocin), rauwolfia derivatives (eg, reserpine), or tricyclic antidepressants (eg, amitriptyline) because they may increase the risk of Dimetapp Decongestant Drops's side effects

Bromocriptine, catechol-O-methyltransferase (COMT) inhibitors (eg, entacapone), or droxidopa because the risk of their side effects may be increased by Dimetapp Decongestant Drops

Guanethidine because its effectiveness may be decreased by Dimetapp Decongestant Drops

This may not be a complete list of all interactions that may occur. Ask your health care provider if Dimetapp Decongestant Drops may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.

How to use Dimetapp Decongestant Drops:

Use Dimetapp Decongestant Drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Take Dimetapp Decongestant Drops by mouth with food, water, or milk to reduce stomach irritation.

Use the dropper that comes with Dimetapp Decongestant Drops to measure your dose. Ask your pharmacist for help if you are unsure of how to measure your dose.

If you miss a dose of Dimetapp Decongestant Drops and are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Dimetapp Decongestant Drops.

Important safety information:

Dimetapp Decongestant Drops may cause dizziness. These effects may be worse if you take it with alcohol or certain medicines. Use Dimetapp Decongestant Drops with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

If your symptoms do not get better within 7 days or if you develop a high fever, check with your doctor.

If you have trouble sleeping, ask your pharmacist or doctor about the best time to take Dimetapp Decongestant Drops.

Do not take diet or appetite control medicines while you are taking Dimetapp Decongestant Drops.

Some of these products contain phenylalanine. If you must have a diet that is low in phenylalanine, ask your pharmacist if it is in your product.

Diabetes patients - Dimetapp Decongestant Drops may affect your blood sugar. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.

Use Dimetapp Decongestant Drops with caution in the ELDERLY; they may be more sensitive to its effects.

Dimetapp Decongestant Drops should be used with extreme caution in CHILDREN younger than 2 years old; safety and effectiveness in these children have not been confirmed.

PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Dimetapp Decongestant Drops while you are pregnant. It is not known if Dimetapp Decongestant Drops are found in breast milk. If you are or will be breast-feeding while you use Dimetapp Decongestant Drops, check with your doctor. Discuss any possible risks to your baby.

When used for longer than a few weeks or at high doses, some people develop a need to continue taking Dimetapp Decongestant Drops. This is known as DEPENDENCE or addiction. If you stop taking Dimetapp Decongestant Drops suddenly, you may have WITHDRAWAL symptoms. These may include depression.

Possible side effects of Dimetapp Decongestant Drops:

All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:

Difficulty urinating; dizziness; headache; nausea; nervousness; restlessness; sleeplessness; stomach irritation.

Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).

See also: Dimetapp Decongestant side effects (in more detail)

If OVERDOSE is suspected:

Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include confusion; hallucinations; irregular or unusually slow or rapid heartbeat; rapid breathing; seizures.

Proper storage of Dimetapp Decongestant Drops:

Store Dimetapp Decongestant Drops at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Dimetapp Decongestant Drops out of the reach of children and away from pets.

General information:

If you have any questions about Dimetapp Decongestant Drops, please talk with your doctor, pharmacist, or other health care provider.

Dimetapp Decongestant Drops are to be used only by the patient for whom it is prescribed. Do not share it with other people.

If your symptoms do not improve or if they become worse, check with your doctor.

Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Dimetapp Decongestant Drops. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.

Issue Date: February 1, 2012

Database Edition 12.1.1.002

More Dimetapp Decongestant resources

Dimetapp Decongestant Side Effects (in more detail)
Dimetapp Decongestant Use in Pregnancy & Breastfeeding
Dimetapp Decongestant Drug Interactions
0 Reviews · Be the first to review/rate this drug

Tuesday, September 27, 2016

Biostrol

Biostrol may be available in the countries listed below.

Ingredient matches for Biostrol

Anastrozole

Anastrozole is reported as an ingredient of Biostrol in the following countries:

Poland

International Drug Name Search

Friday, September 30, 2016

Ingredient matches for Atenolol-CT

DESCRIPTION

CLINICAL PHARMACOLOGY

INDICATIONS AND USAGE

CONTRAINDICATIONS

PRECAUTIONS

ADVERSE REACTIONS

OVERDOSAGE

DOSAGE AND ADMINISTRATION

HOW SUPPLIED

REFERENCES

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

More Collagenase Santyl resources

Compare Collagenase Santyl with other medications

Ingredient matches for Adetide

Ingredient matches for Somnia

Ingredient matches for Becantex

Ingredient matches for Tiapaston

Ingredient matches for Baynas

Scheme

ATC (Anatomical Therapeutic Chemical Classification)

CAS registry number (Chemical Abstracts Service)

Chemical Formula

Molecular Weight

Therapeutic Category

Chemical Name

Foreign Names

Generic Names

Brand Names

What is barium sulfate?

What is the most important information I should know about barium sulfate?

What should I discuss with my health care provider before using barium sulfate?

How should I use barium sulfate?

What happens if I miss a dose?

What happens if I overdose?

What should I avoid before or after using barium sulfate?

Barium sulfate side effects

What other drugs will affect barium sulfate?

More Smoothie Readi-Cat 2 resources

Compare Smoothie Readi-Cat 2 with other medications

Where can I get more information?

Learn more about Infectious Posterior Uveitis

Drug List:

Thursday, September 29, 2016

Ingredient matches for Eetless

Ingredient matches for Bradoral

Ingredient matches for Bactrimel

Ingredient matches for Estreptomicina

Zonalon Cream is used for:

Do NOT use Zonalon Cream if:

Before using Zonalon Cream:

How to use Zonalon Cream:

Important safety information:

Possible side effects of Zonalon Cream:

If OVERDOSE is suspected:

General information:

More Zonalon resources

Compare Zonalon with other medications

Wednesday, September 28, 2016

What is aztreonam?

What is the most important information I should know about aztreonam?

What should I discuss with my health care provider before using aztreonam?

How should I use aztreonam?

What happens if I miss a dose?

What happens if I overdose?

What should I avoid while using aztreonam?

Aztreonam side effects

Aztreonam Dosing Information

What other drugs will affect aztreonam?

More aztreonam resources

Compare aztreonam with other medications

Where can I get more information?

Introduction

Uses for Raltegravir Potassium

Treatment of HIV Infection

Raltegravir Potassium Dosage and Administration

Administration

Oral Administration

Dosage